Qualitative detection of NTRK3 and NTRK1 break apart
A new ZytoDot ® 2C probe for detecting NTRK3 rearrangements
Recently, a second ZytoDot ® 2C probe for detecting rearrangements of the NTRK genes has become available: the new ZytoDot ® 2C SPEC NTRK3 Break Apart Probe (C-3079-100). Together with the already existing ZytoDot ® 2C SPEC NTRK1 Break Apart Probe (C-3078-100), a large range of NTRK rearrangements can be covered now. Both probes are designed for the qualitative detection of NTRK3 and NTRK1 rearrangements in FFPE tissue using the ZytoDot ® 2C CISH implementation Kit.
NTRK1 and NTRK3 rearrangements have been detected in numerous tumor entities. They occur rarely (< 1%) in common entities, but with a high frequency in some rare tumors, e.g., secretory breast carcinoma or infantile fibrosarcoma, making targeted testing by means of in situ hybridization useful here. The fusion genes with different partners are causally involved in tumorigenesis, and the activity of their protein products is inhibited specifically and very effectively by tyrosine kinase inhibitors, such as Larotrectinib and Entrectinib.
Chromogenic in situ hybridization allows stained specimens to be analyzed directly under the light microscope of genomic rearrangements to be assessed in the morphological context. Zytomed Systems provides a kit with all the reagents required to process the specimens, and its components can be reordered individually.
Products
| Product | Manufacturer | Clone | Amount | Status | Order no. | Info | |
|---|---|---|---|---|---|---|---|
| ZytoDot® 2C CISH Implementation Kit | - | 1 Kit (10 Tests) | CE/IVD | C-3044-10 | |||
| ZytoDot® 2C CISH Implementation Kit | - | 1 Kit (40 Tests) | CE/IVD | C-3044-40 | |||
| ZytoDot® 2C SPEC NTRK1 Break Apart Probe | - | 100 µl (10 Tests) | CE/IVD | C-3078-100 | |||
| ZytoDot® 2C SPEC NTRK3 Break Apart Probe | - | 100 µl (10 Tests) | CE/IVD | C-3079-100 |
Further topics
IVDR Update October 2022
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
New NGS-Assay for HRD determination
The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
